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n 1907,Alois Alzheimer, a Bavarian psychia-
trist, reported the case of a middle-aged woman who
developed progressive memory loss and cognitive dis-
orders with autopsy findings of neuritic plaque and neuro-
fibrillary tangles in the cerebral cortex.
1 Thereafter, it
was named as Alzheimer’s disease (AD). However, it
was only in the 1960s that came to be recognized as the
most common cause of dementia in the aged.
2 AD cur-
rently accounts for at least 60% to 70% of cases of
dementia in aged people.
3 In the United States,the total
prevalence of AD is greater than 2.3 million and poten-
tially affects more than 4 million individuals.
4The aver-
age duration of AD is 8 to 10 years,or even shorter.AD
has been ranked as the fourth leading cause of death in
the United States.
2 By the year 2025, over 22 million
patients with dementia are expected around the world.
5,6
Pathology of AD
The pathologic criteria for diagnosis of AD require the
presence of both neuritic plaques and neurofibrillary tan-
gles,together with a progressive decline in cognitive func-
tion.
7The neuritic plaques are composed of aggregations
of β-amyloid (Aβ) and are surrounded by dystrophic neu-
rons and astrocytes.
8-10The neurofibrillary tangles consist
of intraneuronal aggregations of hyperphosphorylation
microtubule–associated protein tau.
11-14 Reduction in
synaptic density and neuronal loss in some specific brain
regions,including the cerebral cortex and hippocampus,
are also important criteria in the diagnosis of AD.
15-19
Clinically,AD is rarely found in people under the age of
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Alzheimer’s disease (AD), the most common cause of
dementia in aged populations, is believed to be caused by
both environmental factors and genetic variations.
Extensive linkage and association studies have established
that a broad range of loci are associated with AD, includ-
ing both causative and susceptibility (risk factor) genes.
So far, at least three genes, APP, PS1, and PS2, have been
identified as causative genes. Mutations in these genes
have been found to cause mainly early-onset AD. On the
other hand, APOE has been identified to be the most
common high genetic risk factor for late-onset AD.
Polymorphisms in the coding region, intron, and pro-
moter region of certain genes constitute another kind of
genetic variation associated with AD. A number of other
genes or loci have been reported to have linkage with AD,
but many show only a weak linkage or the results are not
well reproduced. Currently, the measurable genetic asso-
ciations account for about 50% of the population risk for
AD. It is believed that more new loci will be found to asso-
ciate with AD, either as causative genes or genetic risk fac-
tors, and that eventually the understanding of genetic
factors in the pathogenesis of AD will be important for
our efforts to cure this illness. 
Dialogues Clin Neurosci. 2003;5:17-26.65.In patients under this age,it is called early-onset AD,
and if an obvious familial history can be traced,it is called
familial AD (FAD).The youngest reported case of AD
was found in a 25-year-old person.
6 In patients with age of
onset over 65 years,it is called late-onset AD.The major-
ity of the cases of AD are late-onset.
3,20 AD in patients
without any family history of the disease is called sporadic
AD (SAD).The etiology of AD is not clear.One critical
demographic factor is aging.The prevalence of AD dou-
bles every 5 years after age 60 from less than 1% preva-
lence between 60 and 64 years old to more than 40% in
those aged 85 years or older.
21,22Although environmental
factors, such as education, head trauma, and diet, are
thought to be involved in the pathogenesis of AD,no con-
sistent findings have been reported.
23-26The other demon-
strated risk factor is genetic variation.
27,28
Genetic factors
The first direct evidence of the significant implication of
genetic factors in the pathogenesis of AD came from epi-
demiological studies.AD aggregates within families
29,30:
first-degree relatives of AD patients have a 3.5 times
greater risk of developing the disease than the general
population.Concordance rates were found to be 35% in
dizygotic twins and as high as 80% in monozygotic
twins.
31,32 In particular,many early-onset AD cases exhibit
an autosomal dominant pattern of inheritance.
5,32-34 In addi-
tion, there is a significant association between AD and
Down’s syndrome.
35 However,the involvement of genet-
ics in the pathogenesis of AD is very complicated.
First,as stated above,in some cases AD is an autosomal
dominant inherited disease.Single gene mutation is suffi-
cient to cause the disease. However, it is different from
many typical inherited diseases with single gene mutation,
such as Huntington’s disease,because it shows true genetic
heterogeneity.
36 In autosomal dominant inheritance AD,
mutations in at least three different genes are each suffi-
cient to produce the illness.In addition,variants of these
genes have synergistic effects on the development of late-
onset AD.
17,37,38 Second,the autosomal dominant inherited
types of AD identified so far do not account for the major-
ity of cases of AD (only about 5% to 10% of all cases).
17,20,32
However,it has been shown epidemiologically that more
than 50% (or even up to 80%) of cases of AD have a
genetic determination in a nonmendelian pattern,possi-
bly as an incompletely penetrant trait.It is has been shown
that certain genetic variations predispose to AD,but do
not invariably cause AD (see below).Third,the fact that
the incidence of AD closely correlates with aging suggests
a significant contribution of environmental factors to the
pathogenesis.
2,39 However,the similarities between early-
onset and late-onset AD in terms of clinical and patho-
physiological manifestations suggest a dominant role for
genetic factors in the determination of the phenotypes of
all cases of AD.
17,40All these observations indicate that AD
is a very complex disease genetically.
6,17,20
Amyloid precursor protein
The first single gene that was found to cause AD was the
gene for amyloid precursor protein (APP) on chromo-
some 21.Following linkage analysis,a mutation in APP
was observed in FAD,
41,42 and was later identified as a
mutation at codon 396 (Glu693Gln).
43Thereafter,more
than 16 other APP mutations were reported in 40 families
around the world. The most frequently observed APP
mutation is the London mutation (Val717Ile),which has
been observed in 23 families of various ethnic origins.
44-47
There are three other kinds of mutations at codon 717:
Val717Leu,Val717Phe,and Val717Gly.The second most
frequent mutation is a Dutch mutation (Glu693Gln),
which has been seen in four families.
43 Other reports
include a Swedish mutation at codon 670/671,
48 a Flemish
mutation at codon 692,
49 and others.APP mutations can
result in both FAD and SAD,but the majority of AD cases
caused by APP mutations are FAD.
6,50 Not all APP muta-
tions are pathogenic.
6,17,51 It has been estimated that the AD
caused by APP mutations accounts for only about 0.5%
of all cases of AD.
32
The current hypothesis about the role of APP in AD is the
amyloid cascade theory.
52-54The principle of this theory is
that certain Aβ peptides (which are derived from APP)
are neurotoxic,and that the accumulation of these pep-
tides in the brain is the central event for triggering the
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Selected abbreviations and acronyms
A   -amyloid
AD Alzheimer’s disease
APOE apolipoprotein E
APP amyloid precursor protein
FAD familial Alzheimer’s disease
PS1 presenilin 1
PS2 presenilin 2
SAD sporadic Alzheimer’s disease
SNP single nucleotide polymorphismpathoanatomical and pathophysiological changes in the
brain of AD patients,including the formation of neuritic
plaques and neuronal loss.The finding of APP mutations
in AD dramatically strengthened this hypothesis.The APP
gene encodes for a transmembrane protein containing 770
amino acids,which is extensively expressed on the cell sur-
face.
34,55,56 The function of APP is not yet clearly under-
stood. It is generally considered that APP undergoes a
series of endoproteolytic cleavages during its processing.
53,57
Three kinds of cleavage events are involved, α, β, and γ
cleavage:α cleavage cleaves Lys687 and Leu688 to gener-
ate Aβ peptides with 16 to 17 amino acids (Aβ16 and
Aβ17), while β cleavage cleaves Met671 and Asp672 to
generate  Aβ40 to Aβ42.
58Aβ40 is the dominant product
of the normal cleavage of APP and is found in the normal
aged brain.
51,59-61 In contrast, γ cleavage cleaves Ile712,
Thr714, or Val715 to generate Aβ40, Aβ42, and Aβ43,
respectively,
62,63 and the latter two forms are the major
components of the neuritic plaques observed in the AD
brain.
51,54,64,65 Since they are more fibrillogenic and neuro-
toxic than Aβ40,Aβ42 and Aβ43 are currently considered
to play a central role in the pathological processes of
AD.
66,67Therefore,enhancement of γcleavage is thought to
be a primary reason for why mutant APP causes AD.It
has been shown that most of the APP mutations found in
AD are located in the molecular region around the secre-
tase sites,suggesting that these mutations lead to changes
in the substrate in proteolytic processing. Indeed, it has
been found that many APP mutations in AD significantly
enhance APP cleavage, especially γ cleavage.
63,65,68-72 All
these findings suggest that Aβ metabolism is a key path-
way and should be targeted for therapy.Indeed,a com-
pound that can inhibit γcleavage of APP,a small molecule
that can bind to Aβ to prevent its deposition,or an anti-
inflammatory agent that can diminish the toxic response
associated with Aβ have been the major focuses of our
attempts to cure this illness.
17 Recently, transgenic mice
that have a known AD-causing human mutation have
been immunized with synthetic human Aβpeptide;this led
to a significant reduction in the pathological changes asso-
ciated with the mutant APP and a better performance.
10,12
This could be a novel therapeutic strategy to target Aβ
neurotoxicity in AD.
Presenilin
APP mutations result in only a small proportion of auto-
somal dominant inherited types of AD, which is why
there have been so many linkage studies of other loci
with FAD.The observation of linkage with chromoso-
mal region 14q in some FAD families eventually led to
the discovery of a novel gene, namely presenilin 1
(PS1).
73-76The first PS1 mutation associated with FAD
was reported in 1995.
73,77,78 Since then about 120 kinds of
PS1 mutation have been reported in about 260 families
around the world.Almost all of the reported PS1 muta-
tions are missense and give rise to the substitution of a
single amino acid.So far,only two splicing defect muta-
tions have been reported
79,82; these change the topo-
graphy of the protein in membranes. In addition, the
mutations are most frequently observed in exon 5 (28
mutations),exon 7 (23 mutations),and exon 8 (20 muta-
tions).Mutation in the intron was also found to be able
to produce AD.
83 Of the 120 PS1 mutations reported,the
majority were only found in a single AD family. The
most frequently observed is the AD-associated PS1
mutation on codon 206 (Gly206Ala),and was found in
18 families.The other common mutations are Met146Len
in 12 families,Glu280Ala in 12 families,His163Arg in 10
families, and Pro264Leu in 8 families.Almost all of the
PS1 mutations were found to cause early-onset AD.
However,PS1 mutation on codon 318 (Glu318Gly) was
found in 6 families with SAD and 4 families with FAD,
and even in normal subjects.
84,85Therefore,this mutation
is called a partial pathogenetic factor.
The gene for presenilin 2 (PS2) was first identified on
chromosome 1 in the public nucleotide sequence data-
base, and has an overall 62% homology to PS1.
86,87The
first mutation in PS2 found to associate with FAD was
identified in a German family by linkage studies.
86,87
Thereafter,more than eight kinds of missense mutations
in PS2 were found to cause AD. However, the PS2
mutations do not only produce FAD and late-onset
AD.
74,88There is one known case of a PS2 mutation with
apparent nonpenetrance in an asymptomatic octoge-
narian transmitter of the disease.
74
Currently, most researchers believe that the major
pathological role for mutant PS1 and PS2 in AD comes
from their capacity to facilitate production of amy-
loidogenic Aβ42 peptides.
67,89 This “gain-of-function”
hypothesis has been evidenced by many biochemical
findings and transgenic studies.
89,90 Presenilin is a con-
served polytopic membrane–spanning protein family
consisting of PS1, a 463–amino acid polypeptide, and
PS2, a 448–amino acid polypeptide.
75,86,91 Immunohisto-
chemical analyses indicate that both PS1 and PS2 are
Genetic studies of Alzheimer’s disease - Tang and Gershon Dialogues in Clinical Neuroscience - Vol 5 . No.1 . 2003
19widely expressed in the brain, both in neurons and in
glia,and with the highest levels in the pyramidal neurons
of the hippocampus.
86,92-95 Biochemical studies have
shown that PS1 and PS2 both have eight membrane-
spanning segments with a large hydrophilic loop
between the transmembrane domains 6 and 7, and the
N-terminal and C-terminal both face the cytoplasm.
96-100
This unique structure confers their capacity to interact
with other cytoplasmic proteins.Both of these hypothe-
ses have been supported experimentally:γ-secretase is
an oligomeric complex containing presenilin
91,101-105; and
presenilin itself acts as a γ-secretase.
103,106-110 Indeed,com-
pelling evidence has emerged to support a role for PS1
and PS2 in the γ-secretase proteolysis of APP, Notch (a
transmembrane protein essential for neurogenesis),and
other substrates.
105,107,109,111-116 For example,PS1 facilitates
the proteolysis of APP C-terminal fragments by α- and
β-secretase,
106,109,116-119 which produces Aβ peptides,includ-
ing Aβ42.
84,89,120 Loss of presenilin function results in
diminished Aβ production.
109,121-123The PS1 or PS2 muta-
tions found in AD do not result in loss of func-
tion.
111,120,121,124,125 Instead, these missense mutants signifi-
cantly and specifically enhance γ-secretase cleavage to
generate amyloidogenic Aβ42 peptides.
69,89,90,126,127 All
these findings point to a central role for PS1 and PS2 in
both APP processing and AD pathogenesis.However,a
critical question here is why so many different kinds of
mutation in either PS1 or PS2 produce gain of function
to enhance γ-cleavage. Recently, it has been reported
that polymorphisms in PS1 and PS2 increase risk of
developing late-onset AD.
128The pathway by which these
polymorphisms predispose to AD is not clear.
These findings make it extremely difficult to understand
the role of presenilin-regulated APP metabolism in the
pathogenesis of AD.Moreover,we have recently found
that PS1 plays an important role in adult neurogenesis in
the brain.
129 On the basis of the fact that neuronal loss in
the brain is a hallmark of AD,it is possible that the loss
of function associated with presenilin mutations, and
hence neurogenesis, is another molecular pathway by
which presenilin mutation leads to AD.
It should be noted that, although PS1 mutations are
more common in FAD,the PS1 and PS2 mutations com-
bined are only implicated in about 8% of cases of early-
onset FAD.
32,130-132The majority of AD is late-onset,and
the determination of the contribution of genetic varia-
tions in these patients is fundamental to our under-
standing of the pathogenesis of AD.
Apolipoprotein E
Apolipoprotein E (APOE) was originally reported as a
risk factor for cardiovascular disease.First,a weak linkage
was found between a locus of chromosomal region 19q
and FAD,
133 and then a stronger association between
APOE and late-onset AD was reported in 1993.
134 This
linkage has been well reproduced in subsequent associa-
tion studies and it is now established that APOE is the
most common genetic risk factor for late-onset AD,
133-139
though it appears that there are additional common sus-
ceptibility genes associated with late-onset AD.
38,40,135,140,141
The APOE gene in humans contains three main poly-
morphisms,ε2,ε3,and ε4,of which ε3 is the most common
(75%).The ε3 polymorphism contains a cysteine at codon
112 and an arginine at codon 158.The ε4 polymorphism
represents an arginine at codon 112 and was found to
strongly associate with late-onset AD.
133,139 Persons
homozygous for ε4 have almost a 15-fold higher risk of
developing AD,and persons heterozygous for ε4 have a 3-
fold higher risk than those who do not carry this allele.
142,143
This dose–response relationship provides a strong argu-
ment for the APOE polymorphism being a contributing
factor for AD.The ε2 polymorphism contains a cysteine at
codons 112 and 158,and has also been found to associate
with late-onset AD.
134 In addition,it has been reported that
the ε4 polymorphism or a polymorphism in the promoter
region is associated with early-onset AD.
135,144 Furthermore,
polymorphisms within the promoter regions of the APOE
gene,such as the region at 491 amino acids upstream of the
APOE transcriptional start site (-491 A/T), were also
found to associate with AD.
145-148 It has been shown that
these polymorphisms (ie,at -491 A/T and at the ε4 allele)
are independent genetic risk factors.
37A study of 5.5 kb of
the APOE gene found at least 22 single nucleotide poly-
morphisms (SNPs).These SNPs generate 31 distinct hap-
lotypes and 7 SNPs were found in promoter region.
149A
role for these polymorphisms in pathogenesis of AD has
not been shown.
40
Despite these robust association results,there are still con-
flicting reports. A major discrepant finding came from
studies in African-American and Hispanic populations,
which did not find any association of the ε4 allele with
AD.
150-152Also,it is not clear why some homozygotes of ε4
still do not show any obvious AD symptoms,even when
they are in their nineties. On the other hand, most AD
patients do not harbor an ε4 allele.
17 In addition, some
studies indicate no increased risk factor for AD with 
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153
Japanese,
67,154 or Chinese
155 populations.It is reasonable to
consider that the APOE polymorphism is only a genetic
risk factor,but not a causative gene.This is also evidenced
by the finding that many other factors, such as head
injury,
156,157 spontaneous intracerebral hemorrhage,
158 and
heart surgery,
159 facilitate the association of APOE poly-
morphism with AD.
The mechanism by which the APOE gene is implicated in
AD pathogenesis is still unclear.The current hypothesis is
that APOE ε4/ε2 polymorphisms may affect the production,
distribution,or clearance of Aβ.There is evidence to show
that APOE genotype is a factor affecting the age of onset
of AD with the London APP mutation,suggesting a direct
biochemical interaction between APOE and Aβ.
160-162
However, an open question here is why this synergistic
effect on age of onset is only observed for the London
APP mutation, but not in other mutations such as the
Flemish mutation.
5Another line of evidence to support
this hypothesis comes from the observations that a higher
Aβ plaque burden was observed in AD patients with
APOE ε4 allele than without APOE ε4 allele.
163-165 It has
also been reported that APOE and Aβ may share the
same clearance mechanism,which is through the lipopro-
tein-related receptor,and ε4 competes with Aβ for clear-
ance by the receptor.
166 However,in many cases,changes
in Aβ deposition are not significantly correlated with the
presence of the APOE ε4 allele,which leads to an uncer-
tain status for this hypothesis.
17 Other possible mechanisms
for the involvement of APOE polymorphisms in AD
pathogenesis include (i) the ε4/ε2 allele enhancing the for-
mation of neurofibrillary tangles
167,168;and (ii) the ε4 allele
reducing the normal function of ε3 in maintaining normal
synaptic density.
169,170All these ideas remain hypothetical.
Remarkably, the  ε4/ε2 central theory in the APOE
hypothesis is challenged by the findings of polymorphisms
in promoter regions of APOE that are associated with AD
independently of the ε4 allele.
37This independence indi-
cates that the presence of ε4/ε2 alleles is not the only fac-
tor implicating the involvement of APOE in the patho-
genesis of AD,since it is supposed that the polymorphisms
in the promoter region may alter level of expression of ε3,
but not ε4.
145,147
Other genetic risk factors
The mutations in APP, PS1, PS2,and APOE polymor-
phisms account for less than half of the genetic variance
in AD,which indicates that there must be other suscepti-
bility loci or genetic risk factors in this disease.
171,172 Indeed,
on chromosome 12, at least three genes were found to
associate with AD.One is α2-macroglobulin (A2M).
173,174
Like APOE,A2M is a ligand for a lipoprotein-related
receptor, and its functions are related to the binding,
degradation,and clearance of the Aβ that accumulates in
senior plaques.
175Two A2M polymorphisms were identi-
fied in association with AD,
173 and other positive associ-
ations with AD have been reported
176-180;however,some
negative associations have also been found.
181,182
Another gene with a potential involvement in AD risk is
low-density lipoprotein receptor–related protein (LRP1),
as reported in a study of 128 AD families.
183 LRP1 is the
receptor for Aβ clearance, which might share the same
mechanisms as APOE or A2M.A detailed association
study with a bigger sample size in different ethnic popu-
lation is now required.
A third possible AD gene is synaptobrevin.
184 Synapto-
brevin is a vesicle-associated membrane protein and its
expression is associated with number of synapses.This is
a good candidate gene since it can be used as an index
for synaptic loss or neuronal loss,
184 which is a major
observation in the AD brain.
On chromosome 10,associations between increased risk
for AD and the loci D10S1423,
141,185,186 D10S1211,
141,187 and
D10S1225
188,189 were reported.This variation needs to be
studied further.The gene for insulin-degrading enzyme
on chromosome 10 has also been associated with
AD.
188,190 Since this gene has been shown to degrade Aβ
in primary neuronal culture, it is a good candidate
genetic risk factor for AD. Also, multiple regions on
chromosome 9,
187,189 chromosome 6,
171,172 chromosome
1,
191,192 and chromosome 19
189 have been reported to asso-
ciate with the risk for AD.Other genes reported to asso-
ciate with AD include those for cathepsin D,
37 nerve
growth factor (NGF),
137 FE65 (an adapter protein),
193
LBP-1c/CP2/LSF transcription factor,
193 bleomycin
hydrolase,
193 α1-antichymotrypsin,
193 interleukin-1,
194,195
cyclooxygenase-2,
191,192,196 NOS-3 (NOS, nitric oxide syn-
thase),
197 transferrin C2,
198 and many other genes.
37
However, the exact roles for these genes in the patho-
genesis of AD are not yet clear,and some of these asso-
ciations can be considered as insufficiently replicated.
Nevertheless,they offer hope for progress in the identi-
fication of susceptibility genes, as well as for functional
analysis of the associated gene products, which will fur-
ther contribute to our understanding of AD pathogenesis.
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21Conclusion
Linkage studies and association analysis are the two prin-
cipal strategies of the last 20 years that have led to the
identification of specific gene variants that contributing to
the pathogenesis of AD.The overall conclusion from these
studies is that the majority of AD is complex,is inherited
in a nonmendelian pattern,and involves the interplay of
susceptibility genes with environmental factors.Aging is
still a crucial factor in the onset of this disease.Since the
current genetic associations only account for about 50%
of the population risk for AD,it is believed that more new
loci will be disclosed to associate with AD, either as
causative genes or as genetic risk factors. In the near
future,we would expect linkage,association,and positional
cloning studies with larger samples,and more sophisticated
statistical,genomic,and proteomic analytical methods to
further elucidate the genetic bases of AD. ❏
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Estudios genéticos en la Enfermedad de
Alzheimer
La Enfermedad de Alzheimer (EA), la causa más
común de demencia en poblaciones de senescentes,
se cree que es causada tanto por factores ambienta-
les como por variaciones genéticas. Extensos estudios
de linkage y de asociación han establecido que una
amplia gama de loci están asociados con la EA, inclu-
yendo genes causales y de susceptibilidad (factor de
riesgo). Hasta la fecha se han identificado al menos
tres genes causales: APP, PS1 y PS2. Se ha encontrado
que mutaciones en estos genes causan principal-
mente EA de comienzo precoz. Por otra parte, se ha
identificado a la APOE como el factor de alto riesgo
genético más común para la EA de inicio tardío. Los
polimorfismos en la región de codficación, en el
intrón y en la región promotora de ciertos genes
constituyen otra clase de variación genética asociada
con la EA. Se ha reportado un número de otros
genes o loci que tienen enlaces con la EA, pero
muchos muestran sólo un enlace débil o los resulta-
dos no están bien reproducidos. Actualmente las
asociaciones genéticas medibles dan cuenta de cerca
del 50% de la población en riesgo para EA. Se piensa
que se encontrarán más loci nuevos que se asocien
con la EA, ya sea como genes causales o factores de
riesgo genético, y que en un futuro la comprensión
de los factores genéticos en la patogénesis de la EA
será importante en nuestros esfuerzos para curar
esta enfermedad.
Études génétiques dans la maladie
d’Alzheimer
L’association de facteurs environnementaux et de
variations génétiques semble bien être à l’origine de
la maladie d’Alzheimer (MA), cause la plus fréquente
de démence chez les sujets âgés. Des études de liai-
son et d’association de grande envergure ont établi
qu’un grand nombre de locus sont associés à la MA,
y compris les gènes (facteurs de risque) de suscepti-
bilité et les gènes causals. Jusqu’ici, au moins trois
gènes, APP, PS1 et PS2 ont été  identifiés comme
gènes causals. Les mutations de ces gènes sont res-
ponsables principalement de MA à début précoce.
Par ailleurs, APOE a été identifié comme le facteur
de risque génétique élevé le plus courant pour la
MA à début tardif. Les polymorphismes de la région
codante, l’intron, et la région activatrice de certains
gènes constituent un autre type de variation géné-
tique associé à la MA. Une relation entre plusieurs
autres gènes ou locus et la MA a été rapportée mais,
pour la plupart, le lien est faible ou bien les résultats
sont mal reproduits. Actuellement, les associations
génétiques mesurables expliquent environ 50 % des
risques de la population pour la MA. Il est à prévoir
que plusieurs autres nouveaux locus montreront une
association à la MA, que ce soit comme gènes cau-
sals ou comme facteurs de risque génétique. Ainsi,
la compréhension des facteurs génétiques dans la
pathogenèse de la MA devrait contribuer de façon
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